Methanol Extract of Peltophorum pterocarpum Stem Bark Has Antimalarial Activity and Normalizes Biochemical Changes Induced by Plasmodium berghei Infection

This study evaluated the antimalarial, haematological and biochemical status of Plasmodium berghei Anka 65-infected mice treated with methanol extract of Peltophorum pterocarpum stem bark (MEPT). The acute toxicity profile and phyto-constituents were also evaluated. Thirty mice were divided into 6 groups of 5 mice each. Group 1 served as normal control and received distilled water only. Group 2 was parasitized and untreated. Groups 3-5 were parasitized and treated with 200, 400 and 600 mg/kg b.w. body weight of MEPT respectively. Group 6 was parasitized and treated with 28 mg/kg. b.w. of arthemeter/lumenfantrin combination. Malaria parasitemia were monitored on treatment days 0-3. Antioxidant, liver, kidney and lipid peroxidation status were determined using classical methods 5 days post-treatment. There were dose-dependent reductions in malaria parasitemia percentages of groups 3-5 that are comparable with group 6. In addition, there were dose and duration-dependent increases in malaria chemo-suppression in groups 3-5. The existence of oxidative stress, lipid peroxidation, and kidney and liver dysfunctions were observed in group 2 when compared with group 1. Treatment of groups 3-5 with MEPT and group 6 with arthemeter/lumenfantrin for 4 days restored the biochemical anomalies induced by malaria. The extract was tolerable up to 5,000 mg/kg b.w. of MEPT. The presence of flavonoids, alkaloids, saponins, tannins, steroids, carotenoids, glycosides, anthraquinones, terpenoids and anthocyanins were detected in high amounts while phenols was detected in low amount in MEPT. These suggest that MEPT possesses antimalarial activity and normalizes malaria-modified biochemical changes. These effects might be attributed to its bioactive constituents. Keywords: malaria, Peltophorum pterocarpum, phytochemicals, toxicity, biochemical dysfunctions DOI: 10.7176/ALST/73-05 Publication date: April 30th 201

Zanthoxylum Species: A Comprehensive Review of Traditional Uses, Phytochemistry, Pharmacological and Nutraceutical Applications

Zanthoxylum species (Syn. Fagara species) of the Rutaceae family are widely used in many countries as food and in trado-medicinal practice due to their wide geographical distribution and medicinal properties. Peer reviewed journal articles and ethnobotanical records that reported the traditional knowledge, phytoconstituents, biological activities and toxicological profiles of Z. species with a focus on metabolic and neuronal health were reviewed. It was observed that many of the plant species are used as food ingredients and in treating inflammation, pain, hypertension and brain diseases. Over 500 compounds have been isolated from Z. species, and the biological activities of both the plant extracts and their phytoconstituents, including their mechanisms of action, are discussed. The phytochemicals responsible for the biological activities of some of the species are yet to be identified. Similarly, biological activities of some isolated compounds remain unknown. Taken together, the Z. species extracts and compounds possess promising biological activities and should be further explored as potential sources of new nutraceuticals and drugs

Comparative Study on the Nutritional Properties of Citrullus colocynthis, Irvingia gabonensis and I. wombolu Seeds

Background: The effects of malnutrition due to food insecurity demand continuous and urgent efforts to salvage the situations. There are needs to compare the nutritional and anti-nutritional status of edible plant materials commonly used to help consumers make a scientific-based informed decision.Objective: to determine and compare the nutritional and anti-nutritional contents of three seeds - Citrullus colocynthis, Irvingia gabonensis and I. wombolu.Materials and methods: The seeds sourced from Nsukka Market and were analyzed for mineral, proximate, vitamin and anti-nutrient compositions using standard protocols.Results: The concentration of sodium, copper, magnesium, zinc and phosphorous were higher in C. colocynthis seed compared to Irvingia species. I. wombolu had the highest calcium, and potassium contents. I. gabonensis had the highest iron content. C. colocynthis had the highest protein content, while the two Irvingia seeds had higher total fats, fatty acids, and calorific values compared to C. colocynthis seed. Vitamin C, in C. colocynthis was the least total vitamin content and the least antinutrient.Conclusion: This study demonstrates that seeds of Citrullus colocynthis, Irvingia gabonensis and I. wombolu are rich in nutritive factors, in varying proportions, and are low in antinutrient contents. With the results of this comparative study, consumers are therefore encouraged to make evidence-based decision on the choice of the seed to consume in line with their nutritional and health needs

Lupin-Derived Bioactive Peptides: Intestinal Transport, Bioavailability and Health Benefits

There is a renewed interest on the reliance of food-based bioactive compounds as sources of nutritive factors and health-beneficial chemical compounds. Among these food components, several proteins from foods have been shown to promote health and wellness as seen in proteins such as α/γ-conglutins from the seeds of Lupinus species (Lupin), a genus of leguminous plant that are widely used in traditional medicine for treating chronic diseases. Lupin-derived peptides (LDPs) are increasingly being explored and they have been shown to possess multifunctional health improving properties. This paper discusses the intestinal transport, bioavailability and biological activities of LDPs, focusing on molecular mechanisms of action as reported in in vitro, cell culture, animal and human studies. The potentials of several LDPs to demonstrate multitarget mechanism of regulation of glucose and lipid metabolism, chemo- and osteoprotective properties, and antioxidant and anti-inflammatory activities position LDPs as good candidates for nutraceutical development for the prevention and management of medical conditions whose etiology are multifactorial

Thigh-length compression stockings and DVT after stroke

Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research